Cantor Fitzgerald Downgrades DICE Therapeutics to Neutral, Lowers Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Prakhar Agrawal downgraded DICE Therapeutics (NASDAQ:DICE) from Overweight to Neutral and lowered the price target from $58 to $48.
June 20, 2023 | 4:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
DICE Therapeutics downgraded to Neutral by Cantor Fitzgerald, with a lowered price target of $48.
The downgrade from Overweight to Neutral and the lowering of the price target from $58 to $48 by Cantor Fitzgerald's analyst Prakhar Agrawal may negatively impact DICE Therapeutics' stock price in the short term, as it indicates a less optimistic outlook for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100